Tumour Fas ligand: Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer

Breast Cancer Research

Volumn 4, Issue 5, 2002, Pages

  Reimer, Toralf ^a   Koczan, Dirk ^a   Müller, Heiner ^a   Friese, Klaus ^a   Thiesen, Hans Jürgen ^a   Gerber, Bernd ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Apoptosis; Breast cancer; Fas ligand; Predictive factor; Tamoxifen

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TAMOXIFEN; ANTIESTROGEN; ESTROGEN RECEPTOR; FASLG PROTEIN, HUMAN; LIGAND; MEMBRANE PROTEIN; MESSENGER RNA; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FAS GENE; FASL GENE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTION; PREDICTIVE VALUE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION; BIOPSY; BREAST NEOPLASMS; DRUG RESISTANCE; GENETICS; METABOLISM; MORTALITY; NEOPLASMS, HORMONE-DEPENDENT; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION;

ANTIGENS, CD95; BIOPSY; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FAS LIGAND PROTEIN; FEMALE; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77951537595     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr456     Document Type: Article

References (29)

1. Walczak H, Krammer PH: The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis sytems. Exp Cell Res. 2000, 256: 58-66. 10.1006/excr.2000.4840.
2. Nagata S, Golstein P: The Fas death receptor. Science. 1995, 267: 1449-1456.
3. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J: Melamoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996, 274: 1363-1366. 10.1126/science.274.5291.1363.
4. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996, 184: 1075-1082.
5. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP: Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res. 1999, 59: 59-62.
6. Favre-Felix N, Fromentin A, Hammann A, Solary E, Martin F, Bonnotte B: The tumor counterattack hypothesis revisited: colon cancer cells do not induce T cell apoptosis via the Fas (CD95, APO-1) pathway. J Immunol. 2000, 164: 5023-5027.
7. Arai H, Gordon D, Nabel EG, Nabel GJ: Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA. 1997, 94: 13862-13867. 10.1073/pnas.94.25.13862.
8. O'Connell J, Houston A, Bennett MW, O'Sullivan GC, Shanahan F: Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med. 2001, 7: 271-274. 10.1038/85395.
9. Restifo NP: Not so Fas: re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med. 2000, 6: 493-495. 10.1038/74955.
10. Restifo NP: Countering the 'counterattack' hypothesis. Nat Med. 2001, 7: 259-10.1038/85357.
11. Herrnring C, Reimer T, Jeschke U, Makovitzky J, Krüger K, Gerber B, Kabelitz D, Friese K: Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign breast tumors. Histochem Cell Biol. 2000, 113: 189-194. 10.1007/s004180050438.
12. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D, Botti C, Natali PG, Concetti A, Venanzi FM: Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 2000, 89: 127-132. 10.1002/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO;2-4.
13. Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D: CD95 ligand expression in dedifferentiated breast cancer. J Pathol. 1999, 189: 378-386. 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D.
14. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K, Thiesen HJ: FasL:Fas ratio: a prognostic factor in breast carcinomas. Cancer Res. 2000, 60: 822-828.
15. Ragnarsson GB, Mikaelsdottir EK, Vidarsson H, Jònasson JG, Òlafsdòttir K, Kristjànsdòttir K, Kjartansson J, Ögmundsdòttir HM, Rafnar T: Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer. 2000, 83: 1715-1721. 10.1054/bjoc.2000.1506.
16. Reimer T, Koczan D, Briese V, Friese K, Richter D, Thiesen HJ, Jeschke U: Absolute quantification of human chorionic gonadotropin-β mRNA with TaqMan™ detection. Mol Biotechnol. 2000, 14: 47-57. 10.1385/MB:14:1:47.
17. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998, 351: 1451-1467. 10.1016/S0140-6736(97)11423-4.
18. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17: 2639-2648.
19. Nilsen J, Mor G, Naftolin F: Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. J Neurobiol. 2000, 43: 64-78. 10.1002/(SICI)1097-4695(200004)43:1<64::AID-NEU6>3.0.CO;2-7.
20. Selam B, Kayisli UA, Mulayim N, Arici A: Regulation of Fas ligand expression by estradiol and progesterone in human endometrium. Biol Reprod. 2001, 65: 979-985.
21. Mor G, Munoz A, Redlinger R, Silva I, Song J, Lim C, Kohen F: The role of the Fas/Fas ligand system in estrogen-induced thymic alteration. Am J Reprod Biol. 2001, 46: 298-307. 10.1034/j.1600-0897.2001.d01-16.x.
22. Amant C, Holm P, Xu S, Tritman N, Kearney M, Losordo DW: Estrogen receptor-mediated, nitric oxide-dependent modulation of immunologic barrier function of the endothelium: regulation of Fas ligand by estradiol. Circulation. 2001, 104: 2576-2581.
23. Song J, Sapi E, Brown W, Nilsen J, Tartaro K, Kacinski BM, Craft J, Naftolin F, Mor G: Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest. 2000, 106: 1209-1220.
24. Song RXD, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue W, Wang J, Santen RJ: Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17β-estradiol. J Natl Cancer Inst. 2001, 93: 1714-1723. 10.1093/jnci/93.22.1714.
25. Mor G, Kohen F, Garcia-Velasco J, Nilsen J, Brown W, Song J, Naftolin F: Regulation of Fas ligand expression in breast cancer cells by estrogen: functional differences between estradiol and tamoxifen. J Steroid Biochem Mol Biol. 2000, 73: 185-194. 10.1016/S0960-0760(00)00081-9.
26. O'Connell J, Bennett MW, O'Sullivan GC, O'Callaghan J, Collins JK, Shanahan F: Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol. 1999, 6: 457-463.
27. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: cancer as a site of immune privilege. Immunol Today. 1999, 20: 46-52. 10.1016/S0167-5699(98)01382-6.
28. Gottesman SRS, Edington J: Proliferative and cytotoxic immune functions in aging mice. V. Deficiency in generation of cytotoxic cells with normal lytic function per cell as demonstrated by the single cell conjugation assay. Aging Immunol Infect Dis. 1990, 2: 19-29.
29. Burns EA, Leventhal EA: Aging, immunity, and cancer. Cancer Control. 2000, 7: 513-522.